Hans-Jürgen Stellbrink

Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

Paul E. Sax, Kristine M. Erlandson, Jordan E. Lake et al. · Clinical Infectious Diseases · 2019 · 723 citations · Full text

Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia

Adriano Lazzarin, Bonaventura Clotet, David A. Cooper et al. · New England Journal of Medicine · 2003 · 651 citations · Full text

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

David A. Margolis, Juan González‐García, Hans-Jürgen Stellbrink et al. · The Lancet · 2017 · 492 citations

Treatment And Prevention, Medicine, Phase 2B +8

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

Paul E. Sax, Anton Pozniak, Marisa Montes et al. · The Lancet · 2017 · 385 citations

Hiv/aids Counselling, Antiviral Drug Development, Antiviral Therapy +11

Dolutegravir in antiretroviral-naive adults with HIV-1

Hans-Jürgen Stellbrink, Jacques Reynes, Adriano Lazzarin et al. · AIDS · 2013 · 158 citations · Full text